The AlignMNH Masterclass videos were filmed at the International Maternal Newborn Health Conference in Cape Town, South Africa in May 2023. These videos capture the unique expertise and latest science and evidence on maternal and newborn health that were presented at the conference.
Episode 3: Maternal and Perinatal Death Surveillance and Response (MPDSR) Global Report
Every two minutes, a woman dies from complications related to pregnancy, and every 16 seconds, a stillbirth occurs. Maternal and Perinatal Death Surveillance and Response (MPDSR) is a process for identifying, investigating and responding to maternal and perinatal deaths in order to prevent similar deaths from occurring. Francesca Palestra of the World Health Organization and Mary Mbuo of the London School for Hygiene and Tropical Medicine share important takeaways on MPDSR implementation and information from the upcoming WHO Global Report on MPDSR.
Episode 2: Small Vulnerable Newborns
Worldwide, every fourth baby is born too soon or too small. A new series in The Lancet, released at IMNHC 2023, explores a new conceptual framework bringing together preterm birth, small for gestational age, and low birthweight under the term “small vulnerable newborns” (SVN). In this AlignMNH Masterclass, Dr. Abdu Mohiddin and Dr. Eric Ohuma discuss the important definitions for classifying SVNs, the need for increased measurement and accountability, and the proven and hopeful interventions for prevention.
Learn more and read The Lancet series here.
Episode 1: The E-MOTIVE Trial
Postpartum hemorrhage, or PPH, is the leading cause of maternal mortality worldwide. The E-MOTIVE trial involved training and equipping health providers to rapidly respond to PPH using a low-cost drape to collect and measure blood loss and a clinical bundle of first-response treatments. In this video, three experts who led the trial—Professor Arri Coomarasamy, Dr. Ioannis Gallos, and Professor Sue Fawcus—break down the prevalence of PPH, the structure and implementation of E-MOTIVE, and how, if scaled up, E-MOTIVE could substantially reduce deaths from PPH globally.